Pivotal readout
Regeneron Announces ASH Data
Regeneron plans to present hematology research across 14 abstracts at ASH 2026 in New Orleans, including potentially pivotal Ordspono results in relapsed or refractory marginal zone lymphoma. Lynozyfic presentations will cover updated systemic light chain amyloidosis data and analyses in multiple myeloma; other presentations address investigational therapies for paroxysmal nocturnal hemoglobinuria and blood disorders.
The release announces presentations but provides no numerical efficacy or safety results. The highlighted uses of Ordspono and Lynozyfic in marginal zone lymphoma and amyloidosis, respectively, remain investigational.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.